Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 3/20 | 0.31 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21122218 | 0.82 | PLG (0.38) | LMNAIRAK4KCNA5CD274PDCD1 | |
| SCHEMBL13662178 | 0.78 | IRAK4 (0.32) | LMNAIRAK4CD274PDCD1LG2 | |
| SCHEMBL18289455 | 0.75 | KCNA5 (0.36) | PDK2KCNA5CD274PDCD1MGLL | |
| SCHEMBL4988554 | 0.75 | CD274 (0.32) | LMNAIRAK4CD274PDCD1PDCD1LG2 | |
| SCHEMBL12641530 | 0.73 | VSIR (0.36) | IRAK4PDK2KCNA5CD274PDCD1 | |
| SCHEMBL8001056 | 0.73 | VSIR (0.36) | IRAK4PDK2KCNA5CD274PDCD1 | |
| SCHEMBL14319013 | 0.73 | VSIR (0.36) | IRAK4PDK2KCNA5CD274PDCD1 | |
| SCHEMBL2731412 | 0.72 | — | — | |
| SCHEMBL1649789 | 0.72 | — | — | |
| SCHEMBL22774838 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414071-B2 | Methods of treatment with selective EP4 receptor agonists | PFIZER INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1339678-B1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PROD INC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7192979-B2 | EP4 receptor selective agonist in the treatment of osteoporosis | PFIZER INC. (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1487437-B1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASES | PFIZER PROD INC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20040259921-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
| EP-1487437-A1 | METHODS OF TREATMENT WITH SELECTIVE EP4 RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040254230-A1 | Method for treating ocular hypertension | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | US | disclosed |
| EP-1461026-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6747054-B2 | FOR THERAPY OF LOW BONE MASS, PARTICULARLY OSTEOPOROSIS, FRAILTY, AN OSTEOPOROTIC FRACTURE, A BONE DEFECT, CHILDHOOD IDIOPATHIC BONE LOSS, ALVEOLAR BONE LOSS, MANDIBULAR BONE LOSS, BONE FRACTURE, OSTEOTOMY | PFIZER INC. | 2004-06-08 | — | — | US | disclosed |
| US-6737437-B2 | FOR EXAMPLE, 7-(2S-(3R-HYDROXY-4-PHENYLBUTYL)-5-OXOPYRROLIDIN -1-YL)HEPTANOIC ACID; PROMOTING BONE READSORPTION; BONE LOSS, FRACTURES, AND DEFECTS; FRAILTY; CHILDHOOD IDIOPATHIC BONE LOSS; ALVEOLAR BONE LOSS, OSTEOTOMY; GUM DISEASE; PROSTHETICS | PFIZER INC. | 2004-05-18 | — | — | US | disclosed |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O (US) | 2003-08-07 | — | — | US | disclosed |
| WO-2003047513-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| CN-1413190-A | EP4 receptor selective agonists in treatment of osteoporosis | PFIZER PROD INC (US) | 2003-04-23 | — | — | CN | disclosed |
| US-6552067-B2 | For therapy of osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| WO-2002042268-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O'KEEFE (US) | 2002-04-04 | — | — | US | disclosed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | LMNA 3736/4885IRAK4 404/4885PDK2 2788/4885 |
| US-20040259921-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | LMNA 3655/4885IRAK4 360/4885PDK2 3136/4885 |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | LMNA 3687/4885IRAK4 437/4885PDK2 2854/4885 |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | LMNA 3687/4885IRAK4 437/4885PDK2 2854/4885 |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | LMNA 3736/4885IRAK4 404/4885PDK2 2788/4885 |
| US-20040254230-A1 | Method for treating ocular hypertension | PTGIR, PTGER4, PTGER1 | LMNA 2114/4885IRAK4 1852/4885PDK2 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.